Podium to Practice: EHA 2025 – Multiple Myeloma: LONG-TERM REMISSION AND SURVIVAL AFTER TREATMENT WITH CILTACABTAGENE AUTOLEUCEL IN CARTITUDE-1 PATIENTS WITH RRMM
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Studies / Trials Discussed
S192 – LONG-TERM (≥5 YEAR) REMISSION AND SURVIVAL AFTER TREATMENT WITH CILTACABTAGENE AUTOLEUCEL IN CARTITUDE-1 PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Studies/trials discussed:
S192 – LONG-TERM (≥5 YEAR) REMISSION AND SURVIVAL AFTER TREATMENT WITH CILTACABTAGENE AUTOLEUCEL IN CARTITUDE-1 PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.